PCV44 Real-World Assessment of the Use of Anti-platelet Therapy for Recurrent Stroke Prevention in US Patients without Atrial Fibrillation with Recent Ischemic Stroke or Transient Ischemic Attack

Abstract

Antiplatelet (AP) therapies are the recommended treatment for prevention of recurrent stroke. However, bleeding is a significant risk with any AP therapy. Data on the real-world use of AP therapies in the prevention of recurrent stroke is lacking. This study evaluated current AP treatment patterns in a real-world setting following an initial ischemic stroke (IS) or transient ischemic attack (TIA).